Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
This study has been completed.
Study NCT00631150   Information provided by UCB, Inc.
First Received: February 27, 2008   Last Updated: September 14, 2009   History of Changes

February 27, 2008
September 14, 2009
March 2003
July 2004   (final data collection date for primary outcome measure)
Safety and the tolerability of Keppra in a broad population of patients.
Same as current
Complete list of historical versions of study NCT00631150 on ClinicalTrials.gov Archive Site
Obtain further information about optimal daily dose.
Same as current
 
A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Patients in community-based practices correspond to the 25% of patients who need a first add-on drug when not controlled by their standard monotherapy drug. This was a therapeutic use trial in which the population corresponds more closely to that seen in daily clinical practice.

 
Phase IV
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Epilepsy
Drug: Levetiracetam (Keppra)
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
35
July 2004
July 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • partial onset seizures with or without secondary generalisation with epilepsy.

Exclusion Criteria:

  • hypersensitivity to levetiracetam or other pyrrolidone derivatives or to any of the excipients.
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00631150
Study Director, UCB
N01035
UCB, Inc.
 
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB, Inc.
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP